Skip to main content
GALT logo

GALT · Galectin Therapeutics Inc · Financials

Track GALT — free
$2.69 -0.12 (-4.27%) At close · Nov 20
Market Cap
$271.35M
Shares
100.88M
Volume · Nov 20 257.85K Avg daily vol (3M) 251.29K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Net Income
-$30.84M +34.5%
FY2025 Net Income FY2010–FY2025
Diluted EPS
-$0.48 +36.8%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$23.88M +42.8%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$7.86M $14.29M $36.57M $32.13M $31.74M $23.82M $17.98M $7.47M $6.47M $11.72M $15.33M $13.11M $8.43M $5.69M $4.53M $3.55M $1.07M
$6.93M $5.8M $5.86M $5.94M $6.62M $6.36M $5.47M $5.97M $7.13M $4.53M $6.16M $6.97M $7.01M $6.42M $5.37M $6.86M $3.82M
— — — — — — — — $0 $1000 $7000 $7000 $8000 $7000 $6000 $3000 —
— — $0 $0 $0 $0 $0 $0 $0 $1000 $7000 $7000 $10K $12K $9000 $9000 $12K
$14.79M $20.09M $42.43M $38.07M $38.35M $30.18M $23.44M $13.44M $13.6M $16.25M $21.48M $20.08M $15.43M $12.1M $9.9M $10.41M $4.88M
-$14.79M -$20.09M -$42.43M -$38.07M -$38.35M -$30.18M -$23.44M -$13.44M -$13.6M -$16.25M -$21.48M -$20.08M -$15.43M -$12.1M -$9.9M -$10.41M -$4.88M
$6.72M $7.33M $5.54M $2.79M $1.03M $489K $87K $87K $336K $12K — — — — — — —
$118K $126K $338K $230K $52K $3000 $66K $231K $38K $24K $45K $52K $42K $16K $24K $18K $6000
-$8.4M -$10.75M -$4.61M -$2.99M -$424K -$348K -$21K $144K -$298K $12K $45K $52K -$358K $16K $224K -$506K -$746K
— — — — — — — — — — — — -$400K — — — —
— $0 $0 — — — — — — — — — — — — — —
-$23.19M -$30.84M -$47.05M -$41.07M -$38.78M -$30.53M -$23.47M -$13.29M -$13.9M -$16.24M -$21.44M -$20.03M -$15.79M -$12.09M -$9.68M -$10.92M -$5.63M
-$23.37M -$30.97M -$47.2M -$44.81M -$38.87M -$30.7M -$23.6M -$20.18M -$15.05M -$17.47M -$22.35M -$21.12M -$16.96M -$21.95M -$10.88M -$12.71M -$8.71M
USD/shares -$0.34 -$0.48 -$0.76 -$0.74 -$0.65 -$0.52 -$0.41 — — — — — — — — — —
USD/shares -$0.34 -$0.48 -$0.76 -$0.74 -$0.65 -$0.52 -$0.41 — — — — — — — — — —
shares — 63.9M 62.31M 60.16M 59.39M 58.53M 57.03M 52.24M 39.41M 35.52M 29.22M 24.12M 21.85M 16.87M 15.13M 11.99M —
shares — 63.9M 62.31M 60.16M 59.39M 58.53M 57.03M 52.24M 39.41M 35.52M 29.22M 24.12M 21.85M 16.87M 15.13M 11.99M —
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Operating lease liabilities 2026-09-30 USD 104,000 10-Q filed 2026-11-16
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 62,000
Noncurrent operating lease liabilities
USD 42,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 5.15×
EV/EBIT
—
Peer median 9.10×
P/E (TTM)
—
Peer median 9.17×
Price/Sales (TTM)
—
Peer median 8.26×
Price/Book
—
Peer median 2.14×

Peer medians compare against the 337 similar-size Biotechnology companies (of 593 listed).

Valuation over time computed as of each quarter's filing date

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023
Business Operating Segment -$20,085,000 -$42,433,000 -$38,072,000
Key facts CIK 1133416 CUSIP 363225202 13F (30d) 104 filings 95 filers Visit website Investor relations